MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
April 11, 2007
Billy Fisher
A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders. mark for My Articles similar articles
The Motley Fool
January 25, 2005
Stephen D. Simpson
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. mark for My Articles similar articles
The Motley Fool
October 7, 2004
Brian Gorman
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. mark for My Articles similar articles
The Motley Fool
September 30, 2004
W. D. Crotty
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. mark for My Articles similar articles
The Motley Fool
January 27, 2004
Jeff Hwang
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. mark for My Articles similar articles
The Motley Fool
December 17, 2004
W.D. Crotty
Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news. mark for My Articles similar articles
The Motley Fool
October 4, 2004
Mathew Emmert
Got Merck? The pharmaceutical's investors can't seem to catch a break. mark for My Articles similar articles
The Motley Fool
September 18, 2007
Brian Orelli
New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug. mark for My Articles similar articles
The Motley Fool
March 1, 2006
Rich Duprey
Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware. mark for My Articles similar articles
The Motley Fool
January 26, 2006
Rich Duprey
Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Brian Lawler
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. mark for My Articles similar articles
The Motley Fool
October 23, 2006
Brian Lawler
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. mark for My Articles similar articles
The Motley Fool
February 23, 2005
Stephen D. Simpson
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. mark for My Articles similar articles
The Motley Fool
February 21, 2006
Rick Aristotle Munarriz
Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes. mark for My Articles similar articles
The Motley Fool
April 17, 2007
Brian Lawler
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. mark for My Articles similar articles
The Motley Fool
June 3, 2005
Brian Gorman
Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating. mark for My Articles similar articles
The Motley Fool
November 23, 2004
W.D Crotty
5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Jeannette Park
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. mark for My Articles similar articles
The Motley Fool
August 26, 2005
Stephen D. Simpson
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 23, 2005
Stephen D. Simpson
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. mark for My Articles similar articles
The Motley Fool
November 4, 2005
Rich Duprey
Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Ryan Fuhrmann
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. mark for My Articles similar articles
The Motley Fool
August 22, 2005
Stephen D. Simpson
Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares. mark for My Articles similar articles
The Motley Fool
April 8, 2005
Charly Travers
The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care? mark for My Articles similar articles
The Motley Fool
June 23, 2005
Stephen D. Simpson
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? mark for My Articles similar articles
BusinessWeek
July 25, 2005
Gene G. Marcial
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion. mark for My Articles similar articles
The Motley Fool
November 18, 2004
Lawrence Meyers
Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction. mark for My Articles similar articles
The Motley Fool
July 23, 2007
Brian Lawler
Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition. mark for My Articles similar articles
The Motley Fool
January 10, 2012
Sean Williams
2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair. mark for My Articles similar articles
BusinessWeek
April 21, 2011
Tom Randall
Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines. mark for My Articles similar articles
The Motley Fool
November 8, 2004
Brian Gorman
Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven. mark for My Articles similar articles
The Motley Fool
February 22, 2005
Charly Travers
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. mark for My Articles similar articles
The Motley Fool
December 13, 2005
Rich Duprey
Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors. mark for My Articles similar articles
The Motley Fool
September 7, 2007
Billy Fisher
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. mark for My Articles similar articles
The Motley Fool
April 7, 2005
Brian Gorman
Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments. mark for My Articles similar articles
The Motley Fool
June 23, 2005
Rich Smith
Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal. mark for My Articles similar articles
The Motley Fool
January 31, 2005
Stephen D. Simpson
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. mark for My Articles similar articles
The Motley Fool
December 21, 2004
Brian Gorman
Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads. mark for My Articles similar articles
The Motley Fool
September 25, 2006
Brian Lawler
Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note. mark for My Articles similar articles
The Motley Fool
March 9, 2009
Brian Orelli
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. mark for My Articles similar articles
The Motley Fool
April 10, 2006
Rich Duprey
Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses. mark for My Articles similar articles
BusinessWeek
November 24, 2010
Tom Randall
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Ryan Fuhrmann
Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better. mark for My Articles similar articles
BusinessWeek
March 6, 2006
Amy Barrett
Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster. mark for My Articles similar articles
The Motley Fool
February 25, 2004
Brian Gorman
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. mark for My Articles similar articles
The Motley Fool
May 27, 2005
Stephen D. Simpson
Once More With Merck Merck has had a busy spring, but are investors any better off? mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. mark for My Articles similar articles
Chemistry World
March 13, 2007
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. mark for My Articles similar articles
The Motley Fool
May 16, 2005
Ellen Dowling
Merck Minds Its Manners The drug giant's handbook for its salespeople has Congress offended. Whether the committee thinks its salespeople are charismatic or just plain con artists, Merck's actions will eventually speak louder than its words for patient investors. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Brian Lawler
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. mark for My Articles similar articles